19 May 2026: SERB Pharmaceuticals (“SERB”) and Hansa Biopharma AB (“Hansa”) (Nasdaq Stockholm: HNSA) today announced that they have entered into an agreement under which SERB will acquire the exclusive development and commercialisation rights to Idefirix® (imlifidase) in the European Union, United Kingdom, Switzerland, Norway, Liechtenstein, Iceland and the Middle East and North Africa (MENA) […]

SERB Pharmaceuticals, a global specialty pharmaceutical company focused on rare diseases and medical emergencies, announced that ThyroSafe potassium iodide tablets are now commercially available in a 130 mg dose.

Boston, 12 January 2026: SERB Pharmaceuticals, a global speciality pharmaceutical company focused on rare diseases and medical emergencies, has appointed Dr Peter C. Adamson, MD, FASCO, to its US Board as a Non-Executive Director. Dr. Adamson being exceptional credentials as a globally recognized physician-scientist and leader in oncology drug development and clinical pharmacology. Dr Adamson […]